Qiagen N.V.

  • WKN: A2DKCH
  • ISIN: NL0012169213
  • Land: The Netherlands

Nachricht vom 15.05.2019 | 11:02

QIAGEN N.V.: Release of a capital market information

QIAGEN N.V. / Share Buyback

15.05.2019 / 11:02
Dissemination of a Post-admission Duties announcement transmitted by DGAP -
a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 in conjunction with Article 2 Section (2) and (3) of the Delegated EU Regulation 2016/1052 / Share Repurchase - Interim Reporting With disclosure dated May 10, 2019, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no 2016/1052 the immediate beginning of a fourth tranche of up to USD 50 million under the share repurchase program originally announced on January 31, 2018. The number of shares which have been bought back on the electronic trading platform of the Frankfurt Stock Exchange (XETRA) within the framework of such tranche of the share repurchase program on May 10, 2019 amounts to 51,672 shares. Shares were bought back as follows:

Date            Number of Shares   Average Price     Purchased Volume
                acquired           (EUR)             (EUR)
10 May 2019     51,672             32.1638           1,661,967.87
Total           51,672             32.1638           1,661,967.87


The underlying individual trades are published on the website of QIAGEN N.V. (http://corporate.qiagen.com/investor-relations/share-information/ share-buyback). The total number of shares which have already been bought back within the framework of such tranche of the share repurchase program is 51,672 shares. The purchase of the shares of QIAGEN N.V. was carried out by a financial institution that has been commissioned by QIAGEN N.V. Venlo, 14 May 2019 Managing Board ### Contacts: QIAGEN

Investor Relations                    Public Relations
John Gilardi           +49 2103 29    Dr. Thomas Theuringer  +49 2103 29
                       11711                                 11826
e-mail: ir@qiagen.com                 e-mail: pr@qiagen.com



15.05.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language: English Company: QIAGEN N.V. Hulsterweg 82 5912 PL Venlo Netherlands Internet: www.qiagen.com End of News DGAP News Service

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Wirecard AG: Statement zum Artikel der Financial Times

16. Oktober 2019, 09:01

Aktuelle Research-Studie

Original-Research: Klondike Gold Corp (von First Berlin Equity Research GmbH): BUY Klondike Gold Corp

17. Oktober 2019